HCV / Hepatitis

The US Food and Drug Administration approved Mavyret for adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with mild cirrhosis.

A recent study finds that HBV reactivation occurs earlier and is more severe in HBV/HCV coinfected patients treated with DAA therapy compared with patients treated with IFN-based therapy.

A new study published in the Journal of Hepatology evaluates the risk of HBV reactivation in veterans receiving direct-acting antiviral therapy.

Study finds that hepatitis C patients who had reached sustained virologic response using direct-acting antiviral drugs show a considerably reduced risk of the most common type of liver cancer.

A research team from the Netherlands turns to deep sequencing technology to detect hepatitis C virus resistant variants.

A naturally occurring compound in plums has been found to block the entry of the hepatitis C virus into cultured liver cells.

A recent report coming from the O’Neill Institute for National & Global Health Law takes a closer look at the tools needed to achieve hepatitis C elimination in the United States.

A new study finds hepatitis C virus (HCV) infection to be associated with a 70% increased rate of mortality in in-hospital patients with invasive pneumococcal disease (IPD).

Seniors are at increased risk of hepatitis B, hepatitis C, and HIV. Prevention and early detection of potential infection are critical to avoiding long-term impact.

New drugs for HIV, the growing rate of antibiotic resistance, a new hepatitis C treatment option, and updates on the Ebola outbreak and Lyme disease diagnostics, make up the Top 5 articles for this week.

Findings from a clinical trial from researchers at Hospital Saint Joseph in Marseilles give new hope to patients with HCV in whom treatment with direct-acting antivirals previously failed.

Not much is known about how HIV mono-infection contributes to the development of hepatic steatosis, due to how difficult diagnosis of this condition used to be. Now, with the developement of noninvasive tools, it is easier to diagnose steatosis.

Research presented at Digestive Disease Week examines the factors that contribute to effectiveness of HCV treatment.

The lack of availability of generic DAAs in many other parts of the world increases prices and often limits treatment to people with later stages of the disease.

Researchers may have found a way to broaden the US kidney transplant supply list.

The CDC released new preliminary surveillance data showing that over five years, the number of new hepatitis C infections has nearly tripled in number.

A new study published in the CDC's Morbidity and Mortality Weekly Report details an increasing trend of hepatitis C infection in pregnant women, especially in the state of Tennessee.

This week’s Public Health News Watch focuses on news that the new American Healthcare Act (AHCA), recently approved by the House, reportedly will not cover those with preexisting conditions.

Should clinicians be extra vigilant when deciding who receives antiviral therapy, or are the adverse effects few and infrequent?

In case you missed them, here are our top 5 articles for the week of April 30, 2017.

A study using the Taiwan National Health Insurance research database investigated the efficacy of statin use on preventing the development of liver decompensation in patients with different cirrhosis etiologies.

Many women who are infected with hepatitis B (HBV) during pregnancy go untreated, leaving their offspring at risk for a chronic HBV infection.

Researchers from Zhejiang University in China take a closer look at how the incidence of different infectious diseases have changed in the first decade after the SARS outbreak.

Not much is known about how the genetic makeup of the virus impacts infected individuals, at least, until now.

The World Health Organization just published the first ever Global Hepatitis Report, which notes that the viral hepatitis mortality rate is increasing worldwide, while deaths caused by HIV and tuberculosis continues to drop.

Liver health education seems to be absent from the final draft of the National Academy of Science's Strategy for Eliminating Viral Hepatitis B & C.

Researchers from the Center for Disease Analysis investigated the incidence of hepatitis C in the European Union (EU) and examined the measures that would be needed to achieve the World Health Organization’s ultimate goal of eradicating the disease by 2030.

Doctors Without Borders and humanitarian groups across Europe are coordinating their opposition to Gilead Sciences Inc’s patent for hepatitis C treatment sofosbuvir, the basis for the biopharmaceutical giant’s Sovaldi, Harvoni, and Epclusa drugs.

The US Food and Drug Administration just approved indications for two hepatitis C drugs to be used in pediatric patients.